Ex-GSK Leader Launches ‘Molecular Clamp’ Vaccine Company Vicebio

Will Begin RSV Studies In 2023

 
• By Andrew McConaghie
  
RSV
Vicebio will begin its Phase I study in respiratory syncytial virus in the second half of 2023. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip